This phase II trial is combining a drug (durvalumab) and first line chemotherapy for the treatment of mesothelioma.
This trial is treating patients with Mesothelioma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in.
Other Non-Commercial Sponsor
University of Sydney
A safety run-in phase will be conducted to confirm the tolerability of the standard dose of durvalumab. The safety run-in of the study will be done at a limited number of study sites, once the durvalumab dose is confirmed recruitment will be expanded to all sites for the remainder of the trial.
Durvalumab 1125mg (dose to be confirmed by safety run in) AND chemotherapy (cisplatin 75mg/m2 and pemetrexed 500 mg/m2) are all given intravenously (IV) on day 1, repeated every 3 weeks for a maximum of 6 cycles. If there is no progression, continue durvalumab 1125mg IV on day 1 every 3 weeks for a maximum of an additional 12 cycles (18 cycles in total)
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More